GEN Exclusives

More »

GEN News Highlights

Back to Item »

FDA Clears Astellas’ Myrbetriq for Overactive Bladder

Firm says beta3 adrenergic agonist represents first new class of drug against OAB in 30 years.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Career Development Woes

What do you consider the greatest threat to your career prospects?

More »